{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Complement-mediated+Kidney+Disease",
    "query": {
      "condition": "Complement-mediated Kidney Disease"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T08:11:30.057Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06989359",
      "title": "Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgAN",
        "C3G",
        "Complement-mediated Kidney Disease",
        "IgA Nephropathy (IgAN)",
        "IC-MPGN"
      ],
      "interventions": [
        {
          "name": "ADX-038 Dose Level 2",
          "type": "DRUG"
        },
        {
          "name": "ADX-038 Dose Level 1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ADARx Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2025-08-28",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-05-22T08:11:30.057Z",
      "location_count": 11,
      "location_summary": "Doral, Florida • Miami, Florida • Pembroke Pines, Florida + 8 more",
      "locations": [
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06989359"
    },
    {
      "nct_id": "NCT03316521",
      "title": "First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Complement Mediated Diseases"
      ],
      "interventions": [
        {
          "name": "AMY-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amyndas Pharmaceuticals S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "MALE",
        "summary": "18 Years to 60 Years · Male only"
      },
      "enrollment_count": 50,
      "start_date": "2017-04-24",
      "completion_date": "2017-11-30",
      "has_results": false,
      "last_update_posted_date": "2018-01-16",
      "last_synced_at": "2026-05-22T08:11:30.057Z",
      "location_count": 1,
      "location_summary": "High Point, North Carolina",
      "locations": [
        {
          "city": "High Point",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03316521"
    },
    {
      "nct_id": "NCT03369236",
      "title": "A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "C3 Glomerulopathy",
        "C3 Glomerulonephritis",
        "Dense Deposit Disease"
      ],
      "interventions": [
        {
          "name": "Danicopan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "17 Years to 65 Years"
      },
      "enrollment_count": 13,
      "start_date": "2018-06-12",
      "completion_date": "2020-12-18",
      "has_results": true,
      "last_update_posted_date": "2022-10-14",
      "last_synced_at": "2026-05-22T08:11:30.057Z",
      "location_count": 6,
      "location_summary": "Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03369236"
    },
    {
      "nct_id": "NCT03459443",
      "title": "A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "C3 Glomerulonephritis",
        "C3 Glomerulopathy",
        "Immune Complex Membranoproliferative Glomerulonephritis",
        "IC-MPGN",
        "Dense Deposit Disease"
      ],
      "interventions": [
        {
          "name": "Danicopan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2018-06-20",
      "completion_date": "2021-03-29",
      "has_results": true,
      "last_update_posted_date": "2023-08-21",
      "last_synced_at": "2026-05-22T08:11:30.057Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Stanford, California • New Haven, Connecticut + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03459443"
    }
  ]
}